Tonix Pharmaceuticals Announces Enrollment of Phase 3 RELIEF Trial of TNX-102 SL for Management of Fibromyalgia is Ahead of Schedule

Pat Purcell
Meeting Engagement

Frank Burrell
Scientific Storytelling

Joey Cohen
Medication Adherence

Suma Ramadas, PhD
Medical Affairs

Matthew Durham
Omnidynamic Marketing

Matt Turner
Patient Affordability

Paul Theisen
Patient Acquisition

Bud Bilanich
Success Coach

Stacey Gandler
Brand Nourishment

Liz Kane
Impactful Strategy

Brenda Snow
Authentic Patient Voice

David Linetsky
Point-of-Care Marketing

Daniel Sontupe
Market Access

Amy Giles
Increasing Engagement